- Outflows Accelerate as Crypto Investment Products Face Sluggish Demand
- Goldman Sachs Team: Heavy Asset Stocks Outperform Amid Concerns Over AI Disruption
- U.S. Stocks Move｜Novo Nordisk drops 3% pre-market after cutting semaglutide prices in the U.S. by 50%
- Sotera Health Company's (NASDAQ:SHC) Q4 CY2025: Beats On Revenue
- Michael Saylor compares bitcoin's 45% pullback to Apple's low point in 2013
- Glassnode: Over 400,000 bitcoins have been accumulated in the $60,000 to $70,000 range, forming a dense cost support zone.
- US Stock Market Pre-market Highlights | Trump’s 10% Global Tariff Takes Effect! AMD and Meta Announce Major Strategic Partnership
- Pi Network marks 1-year open mainnet milestone with Pi Coin at all-time lows
- Wintermute Flags Bitcoin $64K–$67K Range
- DigitalOcean (NYSE:DOCN) Beats Q4 CY2025 Sales Expectations, Growth To Accelerate Next Year
- Bowhead Specialty (NYSE:BOW) Surprises With Q4 CY2025 Sales
- Stardust Power Joins Cornerstone Consortium to Support U.S. Critical Minerals and Industrial Base Resilience
- TopBuild to Acquire Johnson Roofing
- Arq Schedules Fourth Quarter & Full-Year 2025 Earnings Conference Call
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
- Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples
- Giant Containers Retained to Design, Deliver New Modular Structures for World-Leading EV Company
- Apogee Therapeutics to Participate in Upcoming March Conferences
- Rekor Systems Announces Strategic On-Shoring of Overseas Engineering Operations to Advance Cost Discipline and Operational Efficiency
- Stablecoins reinvent the intermediary and build bottlenecks, once again
- Yen Drops Amid Dual Setbacks
- Jake Claver to XRP Holders: Your Hardware Wallet Does Nothing When IRS Shows Up
- Pundit Identifies “Extremely Great Indicator” to Predict XRP Price Trends
- Decred defies Bitcoin slump as shrinking supply lifts DCR price
- Why Is BWX Technologies Stock Soaring Tuesday?
- PTLE Announces 1-for-80 Share Consolidation
- WLFI Price In Trouble as Whale Activity Spikes: Is More Downside Ahead?
- Bitcoin and Ethereum ETFs Struggle While XRP ETFs Stay Positive During Market Crash
- Keurig Dr Pepper Inc recently announced its long-term financial targets, projecting that by 2026, the company’s adjusted diluted earnings per share (EPS) will achieve low double-digit percentage growth on a constant currency basis.
- Biopharmaceutical company Fulcrum Therapeutics recently disclosed that by the end of 2025, its total holdings of cash, cash equivalents, and marketable securities will reach $352.3 million.
- Enviri Corporation recently disclosed that an audit revealed a historical accounting error related to a UK pension plan, which had been fully frozen decades ago.
- Nokia Partners With AWS To Transform Network Slicing For Telecom Providers
- Data released by Iovance Biotherapeutics, Inc. shows that its core therapy Lifileucel demonstrates a favorable safety profile.
- Avanos Medical Inc announces the expansion of its transformation plan, expecting these initiatives to deliver incremental annualized savings of $15 million to $20 million by the end of 2026.
- Biopharmaceutical company Fulcrum Therapeutics recently disclosed that by the end of 2025, its total holdings of cash, cash equivalents, and marketable securities will reach $352.3 million.
- First Watch Restaurant Group recently announced its capital expenditure plan for fiscal year 2026, with a total investment expected to reach $150 millions to $160 millions.
- Iovance Biotherapeutics recently announced plans to launch a single-arm registration clinical trial in the second quarter of 2026.
- According to the latest guidance median forecast, the 2026 adjusted EBITDA of Enviri Corporation's two core businesses—Harsco Environmental and Harsco Rail—is expected to see a slight decline compared to 2025.
- Iovance Biotherapeutics recently announced that its tumor-infiltrating lymphocyte (TIL) therapy for soft tissue sarcoma has achieved positive results in its first clinical trial.
- Enviri Corporation recently released a forecast stating that the cumulative net impact of the company’s pension obligations is expected to reach approximately $18 million by the end of 2025.
- Keurig Dr Pepper (NASDAQ:KDP) Exceeds Q4 CY2025 Expectations
- Insmed Incorporated (INSM) Gained from Its Lead Product ARIKAYCE
- Solana Signals Clash as $68 Support Holds While RWA Hits $1.68B
- Galaxy Digital Spotlights Stablecoins and Smart Contracts Reshaping Blockchain Lending
- Saxo Bank: Cryptocurrencies fall as risk-off sentiment rises
- Gilat Receives $39 Million in Orders for Sidewinder ESA Terminals
- Oil: Escalation risks and fair value gap – Commerzbank
- US Stocks Move｜AMD Surges Over 13% Pre-market After Reaching Multi-Billion Dollar AI Equipment Procurement Deal with Meta
- AI agents can’t run wild without on-chain identity | Opinion
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
- XRP Price Tests Crucial Floor, Bearish Bias Strengthens Further
- Crypto markets bleed as bitcoin hovers above liquidation zone
- Pundit: February 29 Will Be Huge for XRP. Just Got Some Massive Inside Info
- Pundit: February 29 Will Be Huge for XRP. Just Got Some Massive Inside Info
- Ocular Therapeutix to Participate in March Investor Conferences
- Ocular Therapeutix to Participate in March Investor Conferences
- Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
- Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
- Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
- Shoals Technologies Group, Inc. Reports Financial Results for Fourth Quarter 2025
- Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
- Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
- Avalo Therapeutics to Participate in Upcoming Investor Conferences
- Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
- Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
- EyePoint Announces Participation at Upcoming Investor Conferences
- iBio to Participate in Upcoming Investor Conferences
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
- Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
- Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook
- Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
- Option Care Health Announces Financial Results for Fourth Quarter and Full Year 2025
- Shoals Technologies Group and ON.energy to Deploy Critical-Power Systems for Leading AI Data-Center Operator
- Mobilicom to Participate at Enforce Tac 2026, Germany's Prominent Trade Fair for Security and Defense
- Uber's Bet On SpotHero Could Set New Standard For Urban Mobility
- Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
- Cipher Digital Provides Fourth Quarter and Full Year 2025 Business Update
- Autolus Therapeutics to Participate in Upcoming Investor Conferences
- Kymera Therapeutics to Participate in Upcoming March Investor Conferences
- DOGE chart targets $0.06 with weak volume, MAs still bearish
- I Would Raise CrowdStrike (CRWD)'s Numbers, Says Jim Cramer
- Chevron (CVX)'s the Only Company I Would Buy Here, Says Jim Cramer
- QuantumScape (QS)'s Been a Tough Own, Says Jim Cramer
- Microsoft (MSFT) Needs a Refresh, Says Jim Cramer
- Elanco (NYSE:ELAN) Surprises With Q4 CY2025 Sales
- "I'm on the Wrong Side of History With Salesforce (CRM)," Says Jim Cramer
- Maybe We Hate Intel (INTC) Too Much, Says Jim Cramer
- Jim Cramer Discusses Cadence Design Systems (CDNS)
- I Trust GE Vernova (GEV) CEO, Says Jim Cramer
- Is GOOGL Stock's Bull Run Over? Charles Moon Is Betting Against Alphabet This March, Expects 4% Decline
- I'm Not a Buyer of Workday (WDAY), Says Jim Cramer
- Jim Cramer Discusses Palo Alto Networks' (PANW) Earnings
- Elon Musk really took the steering wheel off.
- IoTeX L1 resumes operation and completes upgrade
- ANI Pharmaceuticals to Present at Upcoming Investor Conferences
- American Homes 4 Rent (AMH) Reports 2025 Core FFO Growth of 5.4% and $439M Net Income
- Ambiq Micro (AMBQ) Launches soundKIT AI Development Kit for Ultra-Low-Power Edge Devices
